Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma

Nalin Gupta, Liliana C. Goumnerova, Peter Manley, Susan N. Chi, Donna Neuberg, Maneka Puligandla, Jason Fangusaro, Stewart Goldman, Tadanori Tomita, Tord Alden, Arthur Dipatri, Joshua B. Rubin, Karen Gauvain, David Limbrick, Jeffrey Leonard, J. Russel Geyer, Sarah Leary, Samuel Browd, Zhihong Wang, Sandeep SoodAnne Bendel, Mahmoud Nagib, Sharon Gardner, Matthias A. Karajannis, David Harter, Kanyalakshmi Ayyanar, William Gump, Daniel C. Bowers, Bradley Weprin, Tobey J. Macdonald, Dolly Aguilera, Barunashish Brahma, Nathan J. Robison, Erin Kiehna, Mark Krieger, Eric Sandler, Philipp Aldana, Ziad Khatib, John Ragheb, Sanjiv Bhatia, Sabine Mueller, Anu Banerjee, Amy Lee Bredlau, Sri Gururangan, Herbert Fuchs, Kenneth J. Cohen, George Jallo, Kathleen Dorris, Michael Handler, Melanie Comito, Mark Dias, Kellie Nazemi, Lissa Baird, Jeff Murray, Neal Lindeman, Jason L. Hornick, Hayley Malkin, Claire Sinai, Lianne Greenspan, Karen D. Wright, Michael Prados, Pratiti Bandopadhayay, Keith L. Ligon, Mark W. Kieran

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Background. Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods. Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment.

Original languageEnglish (US)
Pages (from-to)1547-1555
Number of pages9
JournalNeuro-Oncology
Volume20
Issue number11
DOIs
StatePublished - Oct 9 2018

Keywords

  • DIPG
  • bevacizumab
  • erlotinib
  • stereotactic biopsy
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma'. Together they form a unique fingerprint.

  • Cite this

    Gupta, N., Goumnerova, L. C., Manley, P., Chi, S. N., Neuberg, D., Puligandla, M., Fangusaro, J., Goldman, S., Tomita, T., Alden, T., Dipatri, A., Rubin, J. B., Gauvain, K., Limbrick, D., Leonard, J., Geyer, J. R., Leary, S., Browd, S., Wang, Z., ... Kieran, M. W. (2018). Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 20(11), 1547-1555. https://doi.org/10.1093/neuonc/noy070